Skip to main content
SpringerLink
Log in

PCV Chemotherapy for Oligodendroglioma: Response Analyzed on T2 Weighted-MRI

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Objective: Because oligodendroglioma are infiltrative tumors, the Mac Donald's response criteria, usually used for solid and contrast-enhanced tumors, seem not to be adapted. To precise more relevant radiological criteria, the radio-logical response of oligodendroglioma to PCV chemotherapy was evaluated on T2 weighted-MRI sequences only.

Methods: 25 patients with oligodendroglioma grade A or B were retrospectively analyzed. They were treated with up to six cycles of PCV standard regimen. Tumor size was calculated before and at the end of the treatment, on T2 weighted-MRI, by two methods: volumetric reconstruction (method 1) and maximal cross-sectional area (method 2). Responses were defined according to new criteria on T2 weighted-MRI.

Results: According to these criteria and with the method 1, 7 of 25 patients (28%) had a partial response to the PCV, 14 patients (56%) had stabilized disease, and 4 patients (16%) had progressive disease. With the method 2, 6 had partial response (24%), 18 had stabilized disease (72%) and 1 had progressive disease.

Conclusion: Response rate to PCV chemotherapy in this study was lower than response observed in the literature. Because of the infiltrative feature of oligodendroglioma, we think that the radiological response of these tumors should be evaluated on T2 weighted-MRI. The two methods of tumor size estimation used in this study were almost equivalent. Then, the maximal cross-sectional area measurement, more practical, could be retained.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kleihues P, Burger PC, Scheithauer BW: Histological typing of tumors of the central nervous system. In: International Histological Classification of Tumors. Geneva, World Health Organization, 1995

    Google Scholar 

  2. Lopes BS, Vanberberg SR, Scheithauer BW: The pathology of oligodendrogliomas. In: Appuzzo MLS (ed) Benign Cerebral Gliomas, Vol. 1, AANS 1995, pp 83–94

  3. Mork SJ, Lindegaard KF, Halvorsen TB: Oligodendroglioma: incidence and biological behavior in a defined population. J Neurosurg 63: 881–889, 1985

    Google Scholar 

  4. Bruner JM: Oligodendroglioma: diagnosis and prognosis. Semin Diag Pathol 4: 251–261, 1987

    Google Scholar 

  5. Rusell DS, Rubinstein LJ: Pathology of tumors of nervous system. 5th edn., Edward Arnold, London, 1989, pp 172–186

    Google Scholar 

  6. Bruner JM: Neuropathology of malignant gliomas. Semin Oncol 21: 126–138, 1994

    Google Scholar 

  7. Coons SW, Jonhson PC, Sheithauer BW, Yates AJ, Pearl DK: Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79: 1381–1393, 1997

    Google Scholar 

  8. Daumas-Duport C: The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. Neurosurgery 4: 885, 1997

    Google Scholar 

  9. Kernohan JW, Maybon RF, Svien HJ, Adson AW: A simplified classification of the gliomas. Proc Staff Meet Mayo Clin 24: 71–75, 1949

    Google Scholar 

  10. Russel DS, Rubinstein LJ: In: Pathology of Tumors of the Nervous System. Baltimore, Williams & Wikins, 1971, pp 147–153

    Google Scholar 

  11. Daumas-Duport C, Tucker M-L, Beuvon F, Cervera P, Varlet P, Chodkiewicz JP: Oligodendrogliomas: Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: A study of 153 cases. J Neuro-Oncol 34: 37–59, 1997

    Google Scholar 

  12. Daumas-Duport C, Monsaigeon V, Szenthe L: Serial stereotactic biopsies: a double histological code of gliomas according to malignancy and 3-D configuration, as an aid to therapeutic decision and assessment of results. Appl Neurophysiol 45: 431–437, 1982

    Google Scholar 

  13. Daumas-Duport C, Sheithauer BW, Kelly PJ: A histologic and cytologic method for the spatial definition of gliomas. Mayo Clinic Proc 62: 435–449, 1987

    Google Scholar 

  14. Daumas-Duport C: Histoprognosis of gliomas. Advances and Technical Standards in Neurosurgery, Vol. 21: 43–72, 1994

    Google Scholar 

  15. Daumas-Duport C: Patterns of tumor growth and problems associated with histological typing of low-grade gliomas. In: Appuzzo MLS (ed) Benign Cerebral Glioma, Vol. 1, 1995, pp 125–147

  16. Daumas-Duport C, Tucker ML, Kolles H, Cervera P, Beuvon F, Varlet P, Udo N, Koziak M, Chodkiewicz JP: Oligodendroglioma. Part II: A new grading system based on morphological and imaging criteria. J Neuro-Oncol 34: 61–78, 1997

    Google Scholar 

  17. Cairncross JG, Macdonald DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23: 360–364, 1988

    Google Scholar 

  18. Cairncross JG, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C Jr, Wainman N, Eisenhauer E: For the national cancer institute of Canada Clinical Trial Group: Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 12: 2013–2021, 1994

    Google Scholar 

  19. Cairncross JG, Macdonald DR, Ramsay DA: Aggressive oligodendroglioma: A chemosensitive tumor. Neurosurgery 31: 78–82, 1992

    Google Scholar 

  20. Macdonald DR, Gaspar LE, Cairncross JG: Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 27: 573–574, 1990

    Google Scholar 

  21. Levin VA, Edwards MS, Wright DC, Seager ML, Pischer-Schimberg T, Townsend JJ, Wilson CB: Modified procarbazine, CCNU and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64: 237–244, 1980

    Google Scholar 

  22. Glass J, Hochberg FH, Gruber L, Louis DN, Smith D, Rattner B: The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 76: 741–745, 1992

    Google Scholar 

  23. Kim L, Hochberg FH, Thornton AF, Harsh IV GR, Patel H, Finkelstein D, Louis DN: Procarbazine, lomustine, and vincristine (PCV) chemotherapy for Grade III and Grade IV oligoastrocytomas. J Neurosurg 85: 602–607, 1996

    Google Scholar 

  24. Kyritsis AP, Yung WK, Bruner J, Gleason MJ, Levin VA: The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 32: 365–371, 1993

    Google Scholar 

  25. Mason WP, Krol GS, DeAngelis LM: Low-grade oligodendroglioma respond to chemotherapy. Neurology 46: 203–207, 1996

    Google Scholar 

  26. Soffietti R, Ruda R, Bradac GB, Schiffer D: PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 43: 1066–1073, 1998

    Google Scholar 

  27. Peterson K, Paleologos N, Forsyth P, Macdonald DR, Cairncross JG: Salvage chemotherapy for oligodendroglioma. J Neurosurg 85: 597–601, 1996

    Google Scholar 

  28. Van Der Bent MJ, Kros JM, Heimans JJ, Pronk LC, Van Groeningen CJ, Krouwer HGJ, Taphoorn MJB, Zonnenberg BA, Tijssen CC, Twijnstra A, Punt Cja, Boogerd W: For the Dutch Neuro-oncology Group: Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine,CCNU,and vincristine chemotherapy. Neurology 51: 1140–1145, 1998

    Google Scholar 

  29. Paleologos NA, David R, Macdonald DR, Vick NA, Cairncross JG: Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology 53: 1141–1143, 1999

    Google Scholar 

  30. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 7: 1277–1280, 1990

    Google Scholar 

  31. Bouffet E, Mornex F, Jouvet A, Thiesse P, Mertens P, Helfre S, Sindou M, Bret P: Assessment of procarbazin, vincristine and lomustine (PCV) association for recurrent oligodendroglioma and mixed glioma. Bull Cancer 84: 951–956, 1997

    Google Scholar 

  32. Watanabe M, Tanaka R, Takeda N: Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology 34: 463, 1992

    Google Scholar 

  33. Daumas-Duport C, Monsaingeon V, N'Guyen JP: Some correlations between histological and CT aspects of cerebral gliomas contributing to the choice of significant trajectories for stereotactic biopsies. Acta Neurochir 33(Suppl): 185–194, 1984

    Google Scholar 

  34. Daumas-Duport C, Monsaingeon V, Blond S: Serial stereotactic biopsies and CT scan in gliomas: correlative study in 100 astrocytomas, oligo-astrocytomas and oligodendrocytomas. J Neuro-Oncol 4: 317–328, 1986

    Google Scholar 

  35. Kelly PJ, Daumas-Duport C, Scheithauer BW: Stereotactic histologic correlations and computed tomography - and magnetic resonance imaging - defined abnormalities in patient with glial neoplasm. Mayo Clin Proc 62: 450–459, 1987

    Google Scholar 

  36. Kelly PJ: Tumor Stereotaxis. WB Saunders, Philadelphia, 1991, pp 296–357

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, University Hospital of Angers, France

    Sylma Diabira

  2. Department of Pathology, University Hospital of Angers, France

    Marie-Christine Rousselet

  3. Department of Neurooncology, Paul Papin Anticancer Center, Angers, France

    Eric Gamelin, Patrick Soulier & Eric Jadaud

  4. Department of Neurosurgery, Paul Papin Anticancer Center, France

    Philippe Menei

Authors
  1. Sylma Diabira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marie-Christine Rousselet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eric Gamelin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Patrick Soulier
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eric Jadaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Philippe Menei
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Diabira, S., Rousselet, MC., Gamelin, E. et al. PCV Chemotherapy for Oligodendroglioma: Response Analyzed on T2 Weighted-MRI. J Neurooncol 55, 45–50 (2001). https://doi.org/10.1023/A:1012986422074

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1012986422074

Search

Navigation